The board of directors of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced that it is expected that the group will record an increase in profit attributable to equity shareholders of not less than 90% for the year ended 31 December 2015, as compared to the year ended 31 December 2014. The expected growth in profit attributable to equity shareholders is primarily attributed to the increase in revenue derived from sales of Kewei (the company's anti- influenza virus product) resulted from the company's continuing educational promotion activities for Kewei, in particular, the rapid growth of turnover in relation to the granules form for children.